Trop2-targeting NIR-II Molecular Probe for Precision Diagnosis of Oral Cancer

After participants enrollment, surgical treatment will be administered based on clinical diagnosis and treatment. During the surgery, excised clinical specimens will undergo incubation with TTP-ICG following this specific procedure:

• Preparation of the incubation solution: TTP-ICG will be dissolved in phosphate-buffered saline (PBS) at room temperature in the dark, with varying concentrations (5, 10, 20 μg/mL).
• Incubation of clinical specimens: The freshly excised clinical specimens will be immersed and gently agitated in the incubation solution for 3, 5, or 10 minutes. Subsequently, they will be rinsed with PBST buffer (PBS with Tween 20) for 5 minutes and dried using absorbent paper.
• Acquisition of NIR-II images: NIR-II images and fluorescent intensities will be captured using the "Digital Precision Medicine (DPM)" NIR-II system, optimized with appropriate parameters.
• Pathological diagnosis and data analysis: Hematoxylin and eosin staining, along with immuno-histochemistry, will be performed. The subsequent correlation between pathological characterization and fluorescent information will be further analyzed.

Inclusion criteria

• Age range: 18-75 years old;

• Patients with oral cancer or benign oral tumors who plan to undergo surgical intervention;

• Preoperative coagulation function test was normal; ④ No serious underlying diseases; ⑤ WHO Physical Status Score 0-2 points;

• Sign the informed consent form;

Exclusion criteria

• Suffering from other invasive malignant tumors;

• Surgery cannot be performed for other serious illnesses; ③ Suffering from mental disorders and unable to sign informed consent forms on their own;

• The subject requests to withdraw from the clinical trial; ⑤ The researchers believe that it is not appropriate for them to continue participating in this clinical trial.